[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anne M. Connolly\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100470940","phase-4-once-weekly-infant-corticosteroid-trial-for-dmd-100470940",false,"NCT05412394","Once Weekly Infant Corticosteroid Trial for DMD","Phase-2 Trial of 5mg\u002Fkg\u002FWeek Prednisolone in Young Boys With DMD","Inclusion Criteria:\n\n* Subjects ages 1 month through 30 months\n* Weakness consistent with Duchenne on exam, creatine kinase ≥ 20 times the upper limit of normal, and genetic mutation known to be causative for DMD.\n\nExclusion Criteria:\n\n* Prior treatment with Glucocorticosteroids","MALE","1 Month","30 Months",{"count":20,"type":21},26,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The hypothesis tested here is that a lower dose of intermittent oral corticosteroids (5mg\u002Fkg\u002Fweek) will be equally effective to the 10mg\u002Fkg\u002Fweek dose.",[27],"Duchenne Muscular Dystrophy",[27,29,30,31],"DMD","Steroid","Muscular Dystrophy","RECRUITING","2025-08-08",{"date":35,"type":36},"2025-08-13","ACTUAL",{"date":38,"type":36},"2021-04-30",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Anne M. Connolly","OTHER",4,""]